AcceXible Speech-Based Screening for Depression and Anxiety in University Students (UAQ, Mexico)
- Sponsor
- Accexible
- Study ID
- NCT07578142
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Anxiety
- Depression - Major Depressive Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - 25 Years
- Healthy Volunteers
- Accepted
Interventions
- Accexible — DEVICESpeech analysis
Study Details
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD). Emerging evidence suggests that depression affects both the acoustic properties and content of speech, making speech analysis a promising candidate as a digital biomarker for early screening. This study evaluates the validity of acceXible, a speech-based machine learning platform, for the detection and monitoring of depression and anxiety in the student population of the Universidad Autónoma de Querétaro, Mexico. AcceXible captures spontaneous speech through open-ended interview tasks and applies automated acoustic and linguistic analysis. The primary objective is to evaluate the validity of the acceXible spontaneous speech analysis system for depression and anxiety screening, assessed against the PHQ and GAD scales as reference standards. Secondary objectives include examining associations between speech-derived variables and other study measures, evaluating participant engagement with digital mental health resources, assessing user satisfaction with the platform, and analyzing longitudinal changes in scores across follow-up assessments.
Key Dates
- First listed
- May 11, 2026
- Start date
- Sep 5, 2026
- Status verified
- May 2026
- Primary completion
- Sep 30, 2027
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 80 participants (estimated)
Primary Outcome Measure
Diagnostic accuracy of acceXible for depression and anxiety screening [ Time Frame: Baseline ]
Central Contacts
- Dra. Olga Patricia García Obregón+52 442 192 1200
Related Studies
- Evaluation of the PACE/PACENET BHL Clinical ProgramRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Creatine for Depressed Male and Female Methamphetamine UsersPHASE3 · Recruiting · Montana State University · Missoula, Montana
- The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and TeensNot Yet Recruiting · Johns Hopkins University · Baltimore, Maryland
- Neurobiological Mechanisms of Aging and Stress on Prospective NavigationRecruiting · Georgia Institute of Technology · Atlanta, Georgia